Cymbalta for Diabetic Peripheral Neuropathic Pain

strict warning: Only variables should be passed by reference in /home/samdeskin/public_html/cymbaltasideeffects.com/modules/book/book.module on line 559.

Cymbalta DiabetesCymbalta is indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy.

Diabetic neuropathy is a common complication of diabetes, in which nerves are damaged as a result of high blood sugar levels (hyperglycemia).

According to Eli Lilly, the drug's manufacturer, the recommended dose for Cymbalta is 60 mg administered once daily. There is no evidence that doses higher than 60 mg confer additional significant benefit and the higher dose is clearly less well tolerated [see Clinical Studies (14.3)]. For patients for whom tolerability is a concern, a lower starting dose may be considered. Since diabetes is frequently complicated by renal disease, a lower starting dose and gradual increase in dose should be considered for patients with renal impairment.

As the progression of diabetic peripheral neuropathy is highly variable and management of pain is empirical, the effectiveness of Cymbalta must be assessed individually. Efficacy beyond 12 weeks has not been systematically studied in placebo-controlled trials.

Eli Lilly fails to mention "withdrawal" as a symptom of discontinuing Cymbalta. Withdrawal symptoms are defined as abnormal physical or psychological features that follow the abrupt discontinuation of a drug that has the capability of producing physical dependence. Withdrawal is a term referring to the feelings of discomfort, distress, and intense craving for a substance that occur when use of the substance is stopped. These physical symptoms occur because the body had become metabolically adapted to the substance. The withdrawal symptoms can range from mild discomfort resembling the flu to severe withdrawal that can actually be life threatening.

Contact Cymbalta Attorneys

We are no longer accepting new Cymbalta withdrawal cases.

Cymbalta LawyersOur firms are investigating problems with symptoms from the discontinuation of use of Cymbalta. Please use the form below to tell us about your situation. We will contact you by phone or email as soon as possible.

WE USE YOUR ANSWERS ON THIS FORM TO DETERMINE WHETHER YOU MAY BE PART OF OUR CYMBALTA LITIGATION. PLEASE FILL OUT THE WHOLE FORM AND GIVE THE CORRECT ANSWERS TO OUR QUESTIONS. YOU WILL HEAR FROM US WITHIN 5 BUSINESS DAYS OF FILLING OUT THIS FORM.

OUR LAW FIRMS WILL NEVER REQUIRE YOU TO PAY ANY OUT-OF-POCKET COSTS. WE WILL NEVER ASK YOU FOR MONEY. THE ONLY THING WE WILL EVER ASK YOU TO PAY FOR ARE YOUR PHARMACY AND MEDICAL RECORDS. THE MONEY WE SPEND ON COSTS IS MONEY WE RISK. WE ONLY GET PAID BACK THIS MONEY IF WE WIN AND ONLY FROM MONEY PAID BY THE DEFENDANTS. According to the applicable law, this paragraph may not apply to residents of Georgia, Virginia, or Washington, or any other state that's law does not allow contingent costs.

Your confidentiality matters. No information, including phone numbers and email addresses will be exchanged, shared or sold to a third party. Any communications to our firm via contact forms, email, phone or U.S. mail, will be treated confidentially. Submissions are made for the purpose of evaluating whether or not our law firm will accept your case and represent you. However, all information contained in your submission will be held confidential. By evaluating your submission we make no representation or agreement to represent you in connection with your claim. Thank you.